Antibiotic-associated diarrhoea (AAD) represents a clinical entity leading to prolonged hospital stays and diagnostic and therapeutic procedures, and results in additional costs. The aim of the present study was to assess the prevalence and characteristics of different bacteria in stools of patients with AAD. The reliability of diagnostic procedures under routine conditions was evaluated. Host factors were also analysed. From June 2002 to April 2003 89 cases of diarrhoea were reported at a hospital unit for internal medicine. Clostridium difficile and Clostridium perfringens toxin enzyme-immunoassays (EIAs), and culture for C. difficile, C. perfringens and Staphylococcus aureus were performed on stool samples from all patients. Toxin production was determined in isolated S. aureus strains. In vitro susceptibility of S. aureus for oxacillin and of C. difficile for vancomycin, metronidazole, linezolid, fusidic acid and tetracycline was tested. Host factors, such as age, comorbidities, antibiotic exposure and contact with other patients, were evaluated. Twenty-six stools were positive for C. difficile toxins by an EIA technique, while C. difficile was cultured from 39. C. difficile was isolated from 21 stools that were EIA negative. Additionally, from 28 stools S. aureus and/or C. perfringens could be isolated. Nine samples contained only S. aureus and/or C. perfringens. Thirty-one stools were negative in all tests. All C. difficile isolates were susceptible to vancomycin and metronidazole. Age >60 years, and diseases of the vascular system, the heart, the kidneys and the lungs were identified as risk factors for acquiring C. difficile in this setting (P values < 0.05). Stool culture for C. difficile was shown to be more sensitive than toxin EIA in this study. Risk factors for the acquisition of C. difficile in outbreak situations seem to differ from risk factors in the normal hospital setting. The role of toxin-producing S. aureus in cases of AAD needs further investigation.
AbrahaoC.,
CarmanR. J.,
HahnH.,
LiesenfeldO.2001; Similar frequency of detection of Clostridium perfringens enterotoxin and Clostridium difficile toxins in patients with antibiotic-associated diarrhoea. Eur J Clin Microbiol Infect Dis 20:676–677
AdesiyunA. A.,
LenzW.,
SchaalK. P.1992; Phage susceptibility, enterotoxigenicity and antibiograms of Staphylococcus aureus strains isolated from human wounds and diarrhoea. Zentralbl Bakteriol 277:250–259[CrossRef]
BarbutF.,
DelméeM.,
BrazierJ. S. & 10 other authors; 2003; A European survey of diagnostic methods and testing protocols for Clostridium difficile
. Clin Microbiol Infect 9:989–996[CrossRef]
BorrielloS. P.,
WelchA. R.,
LarsonH. E.,
BarclayF.1984; Enterotoxigenic Clostridium perfringens: a possible cause of antibiotic-associated diarrhoea. Lancet 1:305–307
FeketyR.,
McFarlandL. V.,
SurawiczC. M.,
GreenbergR. N.,
ElmerG. W.,
MulliganM. E.1997; Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 24:324–333[CrossRef]
FreemanJ.,
WilcoxM. H.2003; The effect of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol 56:126–128[CrossRef]
FrostF.,
CraunG. F.,
CalderonR. L.1998; Increasing hospitalization and death due to Clostridium difficile diarrheal disease. Emerg Infect Dis 4:619–625[CrossRef]
GeorgeW. L.,
SutterV. L.,
CitronD.,
FinegoldS. M.1979; Selective and differential medium for the isolation of Clostridium difficile
. J Clin Microbiol 9:214–219
GravetA.,
RondeauM.,
Harf-MonteilC.,
GrunenbergerF.,
MonteilH.,
ScheftelJ.-M.,
PrévostG.1999; Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD. J Clin Microbiol 37:4012–4019
JangS. S.,
HansenL. M.,
BreherJ. E.,
RileyD. A.,
MagdesianK. G.,
MadiganJ. E.,
TangY. J.,
SilvaJ.Jr,
HirshD. C.1997; Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 25:S266–S267[CrossRef]
KomatsuM.,
KatoH.,
AiharaM. & 8 other authors; 2003; High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 22:525–529[CrossRef]
KyneL.,
HamelM. B.,
PolavaramR.,
KellyC. P.2002; Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile
. Clin Infect Dis 34:346–353[CrossRef]
OedingP.,
AustarheimK.1954; The occurrence of staphylococci in the intestinal content after treatment with antibiotics. Acta Pathol Microbiol Scand 35:473–483
PeláezT.,
AlcalaL.,
AlonsoR.,
Rodriguez-CreixemsM.,
Garcia-LechuzJ. M.,
BouzaE.2002; Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46:1647–1650[CrossRef]
SchwaberM. J.,
SimhonA.,
BlockC.,
RovalV.,
FerderberN.,
ShapiroM.2000; Factors associated with nosocomial diarrhea and Clostridium difficile -associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 19:9–15[CrossRef]
StarrJ. M.,
MartinH.,
McCoubreyJ.,
GibsonG.,
PoxtonI. R.2003; Risk factors for Clostridium difficile colonisation and toxin production. Age Ageing 32:657–660[CrossRef]
StubbsS. L. J.,
BrazierJ. S.,
O'NeillG. L.,
DuerdenB. I.1999; PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463
WongS. S.,
WooP. C.,
LukW. K.,
YuenK. Y.1999; Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34:1–6[CrossRef]